REGENXBIO closes upsized $107.8M equity offering at $9.00/share, a 20% discount
RGNX sits 84% above its 52-week low of $5.455 on elevated volume (3.6× avg).
Summary
An upsized $107.8 million equity offering closed at $9.00 per share, a 20% discount to market, with underwriters exercising the full overallotment option. The raise provides critical funding but dilutes existing shareholders substantially.
Key Events · Financing and Capital Events · RGNX
-
Upsized Offering Closes
The transaction sold 11,671,139 common shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999, with underwriters exercising the full 1,667,250-share overallotment option.
-
Net Proceeds Reach ~$107.8M
After underwriting discounts and expenses, net proceeds are approximately $107.8 million, up from the ~$94 million initially disclosed due to the overallotment exercise.
-
Deep Discount to Market
Priced at $9.00 per share, the offering represents a 20% discount to the $10.01 stock price as of today, reflecting the company's urgent need for capital despite recent positive clinical news.
-
Dilution Impact
The 11.67 million new shares plus 1.11 million warrant shares represent roughly 25% dilution to existing shareholders, based on approximately 51 million shares outstanding prior to the offering.
Analysis · RGNX · Life Sciences
A heavily dilutive equity raise has been finalized, with 11.67 million shares sold alongside pre-funded warrants covering an additional 1.11 million shares — all at $9.00, a 20% discount to the $10.01 market price. Underwriters exercised the full overallotment, pushing net proceeds to approximately $107.8 million. The capital extends the cash runway for a company that faced going-concern doubts just two months ago, but existing shareholders absorb significant dilution. The offering lands amid a volatile period: positive Phase III Duchenne data in May, a $100M AbbVie milestone in June, and now this discounted raise — a mixed signal of clinical promise and urgent funding needs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $10.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $511.3M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.